Spire Global, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Spire Global, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $110.45M | Apr 4, 2025 |
| FY2024 | Dec 31, 2023 | $97.61M | Apr 4, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $71.55M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $110.45M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $97.61M | Apr 4, 2025 |
| FY2023 | Sep 30, 2023 | $4.57M | Mar 3, 2025 |
| FY2023 | Jun 30, 2023 | $621.0K | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $70.77M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $43.38M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $28.49M | Nov 7, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.16M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $39.88M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $38.59M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $17.14M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $24.66M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $18.21M | Nov 7, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.31M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($103.36M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($77.56M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($99.01M) | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | ($38.09M) | Mar 15, 2023 |
| FY2020 | Dec 31, 2020 | ($8.87M) | May 12, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($95.98M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($69.28M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($58.78M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($78.88M) | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | ($67.83M) | Mar 15, 2023 |
| FY2020 | Dec 31, 2020 | ($1.04M) | May 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.67M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $29.24M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $27.65M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $22.07M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $31.62M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $20.75M | Nov 7, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.83M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($18.45M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($36.31M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($45.74M) | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | ($57.99M) | Mar 15, 2023 |
| FY2020 | Dec 31, 2020 | ($421.5K) | May 12, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.78M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $26.58M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $17.35M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $20.99M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $15.42M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $10.31M | Nov 7, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $210.99M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $193.58M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $239.26M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $255.99M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $290.19M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $44.42M | Nov 7, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $98.06M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $205.26M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $201.48M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $164.85M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $99.99M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $93.16M | Nov 7, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.93M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($11.69M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $37.78M | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $91.13M | Apr 4, 2025 |
| FY2023 | Dec 31, 2021 | $190.21M | Mar 3, 2025 |
| FY2022 | Dec 31, 2020 | ($48.74M) | Mar 15, 2023 |
| FY2020 | May 28, 2020 | $0 | May 12, 2021 |
| FY2021 | Dec 31, 2019 | ($18.66M) | Nov 7, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.45M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $14.74M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $51.16M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $49.95M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $53.63M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Nov 7, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($487.34M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($538.65M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($435.29M) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | ($357.73M) | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | ($249.24M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($211.15M) | Nov 7, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.81M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $19.21M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $29.14M | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | $47.20M | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | $109.26M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $15.57M | Nov 7, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $103.07M | Apr 4, 2025 |
| FY2023 | Dec 31, 2023 | $123.12M | Mar 3, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Nov 7, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Apr 4, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 3, 2025 |
| FY2022 | Dec 31, 2021 | 0 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Nov 7, 2022 |